Schizophrenia spectrum disorders are often misunderstood due to stereotypes (homelessness, hospitalization, unfunctionality). In reality, many with a schizophrenia diagnosis are well managed on medications and can remain functional, with occasional relapses. Injectable antipsychotics given monthly can maintain stability for many patients.
Real-world perspective from video case: a high-achieving student experiences psychosis after relocating to Mexico, relapses in college, treatment helps, highlighting variability in illness course and access to resources.
Today’s topics: schizophrenia spectrum disorders, core symptoms, nursing care, a comprehensive vocabulary of positive and negative symptoms, patient teaching about antipsychotics, and application of the nursing process (safety, education, assessment).
For testing purposes, schizophrenia is taught as a stand-alone disease process, though it overlaps with other psychoses and with mood disorders with psychotic features.
Epidemiology and Onset
Global prevalence: about 1 ext{%} of the population.
No consistent differences by race, socioeconomic status, or culture.
Gender differences:
More early-onset risk in males (typically 18extto25 years).
Later onset more common in females (approximately 25extto35 years).
Males generally have greater day-to-day functional impairment.
Comorbidity common across mental health disorders, including:
Mortality risk: people with schizophrenia have a risk of premature death 1extto2imes higher than the general population.
Early signs may precede psychotic break by months to years (e.g., anxiety, phobias, compulsions); historically, similar to dementia where earlier clues are noticed only in hindsight.
Typical illness trajectory often includes recurrent exacerbations interspersed with periods of reduced or absent symptoms; single-episode presentations exist but are less common.
Core Symptoms: Positive vs Negative
Positive symptoms: presence of abnormal thoughts or experiences that should not be present.
Persecutory delusions: belief that one is being harmed or conspired against.
Referential delusions: interpreting external stimuli as having a personal meaning (e.g., TV, songs).
Somatic delusions: belief about bodily functions or sensations as abnormal.
Grandiose delusions: inflated worth, special status, or powers.
Hallucinations: perception without external stimulus; most commonly auditory, but can be visual, tactile, olfactory, or gustatory.
Command hallucinations: voices instructing the patient to perform actions; highest safety risk (self-harm or harm to others).
Disorganized thinking and speech (speech abnormalities): word salad, derailment, tangentiality, circumstantiality, neologisms, echolalia, echopraxia.
Word salad: incoherent, meaningless jumble of words and phrases.
Clang associations: rhyming or phonetic links between words.
Echolalia: meaningless repetition of others’ words.
Thought insertion/deletion: beliefs that thoughts are being inserted into or removed from the mind.
Tangentiality vs circumstantiality: tangentiality never reaches the point; circumstantiality eventually reaches it but with many irrelevant details.
Disorganized or bizarre behavior and appearance; catatonia (see next section).
Negative symptoms: absence or reduction of normal functions.
Flat affect: limited emotional expression.
Alogia: poverty of speech or poverty of content; may be slow or minimal verbal response.
Anhedonia: reduced ability to experience pleasure.
Avolition (avolition/apathy): lack of motivation or initiative to engage in activities.
Anergia: lack of energy.
Asociality: diminished social interactions.
Poor hygiene and grooming.
Cognitive symptoms: impairments in memory, attention, judgment, and problem-solving; may be subtle at first but become more apparent with illness progression.
Other related phenomena:
Hyperreligiosity or spirituality-focused delusions; referential or magical thinking; sometimes pseudo-religious or magical practices.
Sexual and relational distortions in some individuals with psychosis (not universal).
Alterations in perception of self and environment (depersonalization, derealization).
Distinction from bipolar disorder: psychotic features can appear during manic episodes in bipolar disorder and may resemble schizophrenia; for test purposes, the focus is on schizophrenia as a standalone spectrum.
Polydipsia and Hydration Hazards
Polydipsia (psychogenic or primary): excessive water intake.
Patients may drink large volumes of water, sometimes due to dry mouth from antipsychotics or as a compulsive behavior.
In hospital settings, a water pitcher may be restricted for high-risk patients to prevent water intoxication.
Water intoxication pathophysiology: rapid dilution of electrolytes leading to cerebral edema; can be fatal.
Real-world analogies used in teaching: famous radio contest incident where water intoxication led to cerebral edema and death; similar risks observed in infants who dilute formula.
Antipsychotics commonly cause dry mouth, which can contribute to polydipsia if not monitored.
Safety, Assessment, and the Nursing Process
Safety is the top priority for patients with schizophrenia and for staff; escalating behaviors require protection and possibly involvement of colleagues or security.
Early assessment and diagnosis improve prognosis; coding tools and standardized assessments aid early detection.
Primary prevention concepts: awareness of family history and early signs in at-risk youths.
The nursing assessment focuses on:
Symptoms and coping, daily functioning (Maslow’s hierarchy of needs: basic needs like bathing, eating, sleeping).
Risk assessment for self-harm or harm to others, and for unsafe behaviors (e.g., poor judgment).
Safety planning, crisis de-escalation, and the use of supportive communication.
Mental status examination (MSE) and gathering information when patient insight/uncooperativeness limits direct questioning (involving family or previous records).
During acute psychosis, safety and stabilization are prioritized; discharge planning begins at admission and continues through hospitalization.
Consider social determinants: homelessness and lack of robust support systems increase relapse risk and influence discharge planning.
Care planning emphasizes inclusive communication: even if a patient appears disorganized, involve them in discharge planning and care decisions as much as feasible.
Clinician mindset: protect safety of both patient and staff; do not mistake de-escalation for weakness or fear.
Practical nursing assessment and triage: always evaluate for reversible medical contributors (electrolyte imbalance, infection, metabolic issues) that might worsen psychiatric symptoms.
Discharge Planning and Long-Term Management
Discharge planning begins at admission and involves multiple steps:
Identify post-discharge living situation (shelter, family home, assisted living, etc.).
Determine transportation needs for follow-up appointments (monthly injections, psychiatry visits).
Engage family, friends, and community resources for support and relapse prevention.
Coordinate with discharge planners and case managers to ensure a clear follow-up plan.
Maintenance and relapse prevention:
Continued antipsychotic therapy is essential to suppress psychotic symptoms and prevent relapse.
Monthly injections can improve adherence compared to daily oral dosing, which is especially useful for patients with memory or organizational challenges.
Real-world challenges highlighted: during COVID-19, access to monthly injections was disrupted, leading to relapses for some patients previously well-managed.
Outpatient and community resources (e.g., Highland clinic) provide ongoing follow-up and injection administration to improve continuity of care.
Goals of care include returning to baseline functioning where possible, enhancing independence, and providing education about illness and treatment to reduce relapse risk.
Pharmacology: Antipsychotics Overview
Antipsychotics are categorized into generations (for testing and clinical practice, though newer labeling varies by country):
First-generation antipsychotics (FGAs, typical): primarily target positive symptoms but have higher risk of extrapyramidal symptoms (EPS).
Second-generation antipsychotics (SGAs, atypical): address both positive and negative symptoms with fewer EPS, but carry metabolic and hematologic risks.
Third-generation antipsychotics (often considered including aripiprazole): newer agents with potentially fewer side effects and utility in agitation; often more expensive.
Common clinical objective: use antipsychotics to manage acute psychosis and to prevent relapse, with ongoing evaluation of efficacy and tolerability.
Special consideration in elderly with dementia: antipsychotics carry higher mortality risk and are generally used with caution.
Monitoring and risk communication are essential: patients and families should understand potential side effects and warning signs of emergencies (e.g., NMS).
TD (Tardive Dyskinesia): involuntary, repetitive movements of the mouth, tongue, lips; often irreversible if developed.
Other adverse effects: anticholinergic effects (dry mouth, dry eyes, constipation, urinary retention), sedation, weight gain less pronounced than SGAs but still possible.
Serious but rare adverse event: Neuroleptic Malignant Syndrome (NMS): medical emergency with hyperthermia, autonomic instability, severe rigidity, altered mental status; requires immediate recognition and treatment.
Management of EPS: anticholinergic medications (e.g., benztropine, diphenhydramine) or dose adjustment.
Monitoring for motor side effects is critical (e.g., noticing a shuffling gait that worsens with dosage changes).
Discreet clinical tip: dopamine blockade can be inferred from movement symptoms; nurses should monitor for new or worsened EPS and adjust treatment accordingly.
Practical note: some clinicians employ a strategy of listed management around side effects (e.g., using propranolol for akathisia).
Second-Generation Antipsychotics (SGAs)
SGAs address both positive and negative symptoms with lower risk of EPS but carry other risks:
Weight gain and metabolic syndrome (hyperlipidemia, hypertension, insulin resistance, nonalcoholic fatty liver disease).
Possible leukopenia or neutropenia with certain agents (e.g., clozapine).
Clozapine carries the highest risk of agranulocytosis; requires regular blood monitoring.
Notable SGAs and considerations:
Clozapine (clozapine): effective for treatment-resistant schizophrenia; risk of agranulocytosis and granulocytosis; requires WBC monitoring (weekly during initial period, then less frequently); higher risk of weight gain and metabolic issues; rare but serious infection risk with neutropenia surveillance.
Risperidone, Olanzapine, Quetiapine, Ziprasidone, Ziprasidone, etc.: varying profiles; many associated with metabolic syndrome and weight gain; clozapine is the exception with hematologic monitoring.
Clozapine monitoring specifics:
WBC monitoring is essential, especially in the first six months; fever or sore throat requires prompt evaluation due to infection risk associated with neutropenia.
General SGAs benefit: lower EPS risk than FGAs, making them more tolerable for many patients; however, metabolic monitoring (weight, glucose, lipids) is essential.
Third-Generation Antipsychotics
Aripiprazole (Abilify): a commonly discussed third-generation antipsychotic with relatively favorable side-effect profile; used for agitation and as a PRN option in inpatient settings.
Considerations: higher cost but often better tolerability; still requires monitoring for metabolic effects and other adverse events, though at lower rates for EPS.
Practical point: third-generation agents may be used as alternatives to FGAs/SGAs when side effects or adherence concerns are prominent.
Side Effects by Generation and Monitoring Plan
FGAs: higher risk of extrapyramidal symptoms (EPS), tardive dyskinesia, and anticholinergic effects; risk of NMS (rare but medical emergency).
SGAs: lower EPS risk; higher risk of metabolic syndrome, weight gain, glucose dysregulation, dyslipidemia; clozapine risk of agranulocytosis requiring WBC monitoring.
Specific monitoring strategies:
For clozapine: regular complete blood counts (CBCs) with differential; watch for signs of infection (fever, sore throat); counsel about infection risk.
For SGAs: monitor weight, BMI, fasting glucose, and lipid panels; screen for diabetes risk, cardiovascular risk factors.
For FGAs: monitor for EPS and TD using standardized scales; assess for signs of NMS (fever, rigidity, autonomic instability).
Anticholinergic side effects: dry mouth, dry eyes, constipation, urinary retention; manage with hydration, sugar-free lozenges, fiber; use caution with elderly or constipated patients.
Other side effects: sedation, orthostatic hypotension, sedation, metabolic changes (especially with SGAs).
Patient education: emphasize consistent dosing, potential need for injections, and recognizing early warning signs of adverse effects.
Special Considerations: Neuroleptic Malignant Syndrome and Safety
Neuroleptic Malignant Syndrome (NMS): a rare but life-threatening reaction to antipsychotics; symptoms include hyperthermia, severe muscle rigidity, autonomic instability, altered mental status, and diaphoresis.
Immediate action: discontinue antipsychotic, provide supportive care, and initiate emergency medical treatment.
Importance of recognizing NMS early in inpatient settings to prevent progression.
Diagnostic and Therapeutic Communication Tips for Clinicians
When a patient reports hearing voices or other psychotic symptoms:
Do not dismiss or minimize; ask: "What are the voices telling you to do?" to assess risk to self or others, including potential command hallucinations.
Use non-confrontational language; reorientation should be gentle and not a power struggle.
If a patient has a delusion about something harmless or harmlessly bizarre, avoid direct confrontation; redirect or validate safely without endorsing the delusion.
Communication strategies during acute psychosis:
Avoid reinforcing paranoia; provide a stable, calming environment; use clear, simple language; involve family when appropriate.
On higher acuity units, some patients may request PRN medications to manage escalating symptoms; acknowledge their insight and document accordingly.
Safety planning: assess potential risks to self or others; escalate as needed; prioritize staff safety as well as patient safety.
Assessment approach: integrate medical assessments (electrolytes, infections, glucose) to rule out reversible contributors to psychiatric symptoms.
Discharge planning requires patient involvement and supports continuity of care after leaving hospital; consider social determinants (housing, transportation, access to follow-up care).
Case Example and Testing Concepts
Testable concept: a patient with reported listening to something in a corner (hallucination) should be asked what they are hearing rather than dismissing the experience or contradicting them.
Correct approach: "What are you hearing?" to assess safety and risk rather than saying, "There is nobody there."
A realistic test focus includes recognizing positive symptoms (delusions, hallucinations, disorganized speech) and differentiating them from negative symptoms; however, exam questions may emphasize symptomatic recognition and safety planning rather than strict taxonomy.
Practical Notes for Practice and Studying
Early diagnosis and intervention lead to better prognosis across disease processes; apply the same principle to schizophrenia spectrum disorders.
For exam study, focus on recognizing core symptoms, safety considerations, and the general pharmacology of antipsychotics (FGAs, SGAs, and third-generation agents), including common side effects and monitoring needs.
Study tip suggested in the lecture: handwritten notes or concept maps may improve memory and understanding; consider organizing drugs by generation with side effects under each group.